ArticleThe Journal of pathology2019
Activating mutations in the MAP-kinase pathway define non-ossifying fibroma of bone.
Article in The Journal of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- What's new in pediatric bone sarcomas and benign bone tumors.Journal of children's orthopaedics · 2026Article
- Trametinib for multiple non-ossifying fibromas due to KRAS mosaic mutations: two case reports.Communications medicine · 2026Article
- Unveiling a Silent Bone Lesion: Pathological Fracture in a Child With Non-Ossifying Fibroma.Clinical case reports · 2026Article
- Diagnostic and Treatment Strategies for Adult Non-Ossifying Fibromas: A Case Report and Literature Review.The American journal of case reports · 2026Review
- Surgically Treated Benign Bone Tumors and Tumor-like Conditions in the Pediatric Population-A 10-Year Institutional Experience.Children (Basel, Switzerland) · 2025Article
- Non-Ossifying Fibromas: A 2025 Review.Journal of clinical medicine · 2025Review
- Recent advances in molecular profiling of bone and soft tissue tumors.Skeletal radiology · 2024Review
- Jaffe-Campanacci syndrome; a case series and review of the literature.BMC musculoskeletal disorders · 2024Review
- An unusually aggressive multiple non-ossifying fibroma of the distal tibia and fibula: A case report.Bone reports · 2023Article
- [Bone tumors in children and adolescents].Pathologie (Heidelberg, Germany) · 2023Review
- DNA methylation profile discriminates sporadic giant cell granulomas of the jaws and cherubism from their giant cell-rich histological mimics.The journal of pathology. Clinical research · 2023Article
- Brown Tumour in Chronic Kidney Disease: Revisiting an Old Disease with a New Perspective.Cancers · 2023Review
- Edema-like marrow signal intensity (ELMSI) associated with nonossifying fibroma (NOF) on MRI: an uncommon finding in a common bone lesion.Skeletal radiology · 2023Article
- Article
- KRAS codon 12 mutations characterize a subset of de novo proliferating "metaplastic" Warthin tumors.Virchows Archiv : an international journal of pathology · 2023Article
- Giant cell tumor of bone: An update, including spectrum of pathological features, pathogenesis, molecular profile and the differential diagnoses.Histology and histopathology · 2023Review
- Case Report: Non-ossifying fibromas with pathologic fractures in a patient withFrontiers in genetics · 2023Article
- Oestrogen receptor expression distinguishes non-ossifying fibroma from other giant cell containing bone tumours.Virchows Archiv : an international journal of pathology · 2022Article
- [Giant cell-containing tumors of bone and differential diagnoses].Der Pathologe · 2022Review
- Non-ossifying fibromas and fibrous cortical defects around the knee - an epidemiologic survey in a Japanese pediatric population.BMC musculoskeletal disorders · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-ossifying fibroma (NOF), which occasionally results in pathologic fracture, is considered the most common benign and self-limiting lesion of the growing skeleton. By DNA sequencing we have identified hotspot KRAS, FGFR1 and NF1 mutations in 48 of 59 patients (81.4%) with NOF, at allele frequencies ranging from 0.04 to 0.61. Our findings define NOF as a genetically driven neoplasm caused in most cases by activated MAP-kinase signalling. Interestingly, this driving force either diminishes over time or at least is not sufficient to prevent autonomous regression and resolution. Beyond its contribution to a better understanding of the molecular pathogenesis of NOF, this study adds another benign lesion to the spectrum of KRAS- and MAP-kinase signalling-driven tumours. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Indexed as
Identifiers
30549028What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.